Results 31 to 40 of about 688 (142)
Management of Hypertension with Female Sexual Dysfunction
Medicina, 2022 Female sexual dysfunction (FSD) in hypertension has been less studied than male sexual dysfunction, and antihypertensive agents’ impact on female sexual function is not defined.
Qing Zhong, Yuri Anderson
doaj +1 more source
Modern pharmacological treatments of sexual dysfunction in women: a narrative review [PDF]
Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2020 Introduction: Sexual dysfunction is one of the most common disorders in women. So far, researchers have examined various treatments to promote women's sexual health.
Marzieh Saei Ghare Naz +2 more
doaj +1 more source
Coverage of New Drugs in Medicare Part D
The Milbank Quarterly, Volume 100, Issue 2, Page 562-588, June 2022., 2022 Policy Points Only a small minority of new drugs in “nonprotected” classes are widely covered by Part D plans nationwide in the year after US Food and Drug Administration (FDA) approval. Part D plans frequently apply utilization management restrictions such as prior authorizations to newly approved drugs in both protected and nonprotected classes. Drug
HUSEYIN NACI +5 more
wiley +1 more source
Acta Obstetricia et Gynecologica Scandinavica, Volume 101, Issue 6, Page 657-692, June 2022., 2022 Abstract In recent years, LASER has been introduced as a minimally invasive treatment for a broad range of vaginal and vulvar symptoms and diseases. However, the efficacy and safety of vaginal and vulvar LASER has continuously been questioned. The aim of this study is to create an overview of the current literature and discuss the controversies within ...
Olivia Engholt Mortensen +2 more
wiley +1 more source
Pharmaceuticals, 2023 (1) Background: Genitourinary syndrome of menopause (GSM) is a medical condition that can affect breast cancer survivors (BCS). This is a complication that often can occur as a result of breast cancer treatment, causing symptoms such as vaginal dryness ...
Lucia Merlino +9 more
doaj +1 more source
New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review
Medicina, 2022 Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus and lower urinary tract. This condition is related to hypoestrogenism consequent to menopause onset but is also due to the hormonal decrease after adjuvant
Vittoria Benini +9 more
doaj +1 more source
Ospemifene Displays Broad-Spectrum Synergistic Interactions with Itraconazole Through Potent Interference with Fungal Efflux Activities [PDF]
, 2020 Azole antifungals are vital therapeutic options for treating invasive mycotic infections. However, the emergence of azole-resistant isolates combined with limited therapeutic options presents a growing challenge in medical mycology. To address this issue,
Seleem, Mohamed N +9 more
core +1 more source
Drugs in Context, 2020 Pelvic floor muscle atrophy and collagen loss in connective tissue due to declining estrogen production in women as they age may underlie the increasing prevalence of urge and stress incontinence.
Zuramis Estrada Blanco +2 more
doaj +1 more source
, 2023 The Obstetrician &Gynaecologist, Volume 25, Issue 4, Page 250-251, October 2023.
Shagaf Bakour
wiley +1 more source
Non-oestrogenic modalities to reverse urogenital aging
Menopause Review, 2021 Urogenital aging is a common process affecting all women in the post-menopausal period of their life, and it is substantially due to oestrogen deprivation after ovarian function cessation.
Simone Garzon +5 more
doaj +1 more source